In the search bar below, enter either a DNA or protein change to determine amenability.

You can use this search tool to find out whether a specific GLA variant has been listed in the Full Prescribing Information as amenable to treatment with Galafold. The current list of amenable GLA variants can also be found in the Full Prescribing Information.

This search bar is intended only for Healthcare Professionals licensed to practice in the United States.

For DNA Change

Please use format c.#A>B or c.A#B for DNA changes, where 'c.' is optional; # indicates a number; A and B are letters. Examples: c.8T>C or c.T8C

For Protein Change

Protein changes can be written as either a single-letter or three-letter code. For example, p.(L3P) can be written as is or written as p.(Leu3Pro), where the ‘p.’ and ‘()’ is optional in both cases.

Whether a certain amenable GLA variant in a patient with Fabry disease is disease-causing or not should be determined by the prescribing physician (in consultation with a clinical genetics professional, if needed) prior to treatment initiation. Consultation with a clinical genetics professional is strongly recommended in cases where the amenable GLA variant is of uncertain clinical significance (VUS, variant of uncertain significance) or may be benign (not causing Fabry disease).

*Note: This is only for searching mutiple GLA gene variants on the same chromosome.

In the search bars below, enter up to 3 GLA variants to determine amenability.

You can use this search tool to find out whether a specific GLA variant has been listed in the Full Prescribing Information as amenable to treatment with Galafold. The current list of amenable GLA variants can also be found in the Full Prescribing Information.

This search bar is intended only for Healthcare Professionals licensed to practice in the United States.

For DNA Change

Please use format c.#A>B or c.A#B for DNA changes, where 'c.' is optional; # indicates a number; A and B are letters. Examples: c.8T>C or c.T8C

For Protein Change

Protein changes can be written as either a single-letter or three-letter code. For example, p.(L3P) can be written as is or written as p.(Leu3Pro), where the ‘p.’ and ‘()’ is optional in both cases.

Whether a certain amenable GLA variant in a patient with Fabry disease is disease-causing or not should be determined by the prescribing physician (in consultation with a clinical genetics professional, if needed) prior to treatment initiation. Consultation with a clinical genetics professional is strongly recommended in cases where the amenable GLA variant is of uncertain clinical significance (VUS, variant of uncertain significance) or may be benign (not causing Fabry disease).